Next-generation sequencing using microfluidic PCR enrichment for molecular autopsy

  • Hariharan Raju (Creator)
  • James S. Ware (Creator)
  • Jonathan R. Skinner (Creator)
  • Paula L. Hedley (Creator)
  • Gavin Arno (Creator)
  • Donald R. Love (Creator)
  • Christian Van Der Werf (Contributor)
  • Jacob Tfelt-hansen (Creator)
  • Bo Gregers Winkel (Creator)
  • Marta C. Cohen (Creator)
  • Xinzhong Li (Contributor)
  • Shibu John (Contributor)
  • Sanjay Sharma (Creator)
  • Steve Jeffery (Creator)
  • Arthur A. M. Wilde (Creator)
  • Michael Christiansen (Creator)
  • Mary N. Sheppard (Creator)
  • Elijah R. Behr (Creator)

Dataset

Description

Abstract Background We aimed to determine the mutation yield and clinical applicability of “molecular autopsy” following sudden arrhythmic death syndrome (SADS) by validating and utilizing low-cost high-throughput technologies: Fluidigm Access Array PCR-enrichment with Illumina HiSeq 2000 next generation sequencing (NGS). Methods We validated and optimized the NGS platform with a subset of 46 patients by comparison with Sanger sequencing of coding exons of major arrhythmia risk-genes (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, RYR2). A combined large multi-ethnic international SADS cohort was sequenced utilizing the NGS platform to determine overall molecular yield; rare variants identified by NGS were subsequently reconfirmed by Sanger sequencing. Results The NGS platform demonstrated 100% sensitivity for pathogenic variants as well as 87.20% sensitivity and 99.99% specificity for all substitutions (optimization subset, n = 46). The positive predictive value (PPV) for NGS for rare substitutions was 16.0% (27 confirmed rare variants of 169 positive NGS calls in 151 additional cases). The overall molecular yield in 197 multi-ethnic SADS cases (mean age 22.6 ± 14.4 years, 68% male) was 5.1% (95% confidence interval 2.0–8.1%), representing 10 cases carrying pathogenic or likely pathogenic risk-mutations. Conclusions Molecular autopsy with Fluidigm Access Array and Illumina HiSeq NGS utilizing a selected panel of LQTS/BrS and CPVT risk-genes offers moderate diagnostic yield, albeit requiring confirmatory Sanger-sequencing of mutational variants.
Date made available23 Jul 2019
Publisherfigshare
  • Next-generation sequencing using microfluidic PCR enrichment for molecular autopsy

    Raju, H., Ware, J. S., Skinner, J. R., Hedley, P. L., Arno, G., Love, D. R., Van Der Werf, C., Tfelt-hansen, J., Winkel, B. G., Cohen, M. C., Li, X., John, S., Sharma, S., Jeffery, S., Wilde, A. A. M., Christiansen, M., Sheppard, M. N. & Behr, E. R., 23 Jul 2019, In: BMC Cardiovascular Disorders. 19, 1, p. 174

    Research output: Contribution to journalArticlepeer-review

    Open Access
    File
    89 Downloads (Pure)

Cite this